A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

• Status: Completed
• Trial end date: 2020-11-26
• Target enrollment: 0
• Participant gender: All

Summary

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Male or female between the ages of 18 and 75 years.

• Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.

• Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).

• Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).

Exclusion Criteria:

• Have non-plaque forms of psoriasis.

• Drug-induced psoriasis.

• Current active infection.

• Infected with Mycobacterium tuberculosis (TB).

• Have any history of malignancies.

• Require treatment with prohibited concomitant medications(s).

• Positive for hepatitis B or C, or human immunodeficiency virus (HIV).